Pharmaceutical Co-Development Agreement

„A successful biopharmaceutical company needs a pipeline of patented molecules that can become next-generation therapeutic drugs. Patent protection is one of the most important aspects of safeguarding the company`s assets and shareholder investments,“ commented Dr. Guy Chamberland, CEO and CRO of Tetra. The analysis of actual contractual agreements allows us to assess the following: MAKScientific is a recognized world leader in endocannabinoid research and drug development. MAKScientific has developed a pipeline of small molecular drugs that target cannabinoid receptors (CB1 and CB2) as well as other targets involved in the endocannabinoid system. As part of this agreement, MAKScientific will develop new molecules that will be evaluated by Tetra to detect possible efficacy in various indications such as cancer, pain and inflammation, as well as other potential Tetra targets. About AOP Orphan Pharmaceuticals AG AOP is a pharmaceutical company specializing in the development and commercialization of drugs for rare and complex diseases in hematology/oncology, cardiovascular diseases, metabolic disorders and neurology. The company is present in all countries of Central Europe and the Middle East. AOP also markets its products in Southeast Asia, South Africa and South America with a number of distributors. The company is headquartered in Vienna, Austria.

For more information, see „Tetra is poised for a strong future and is clearly formed into a biopharmaceutical company of Rx products based on the discovery and development of cannabinoids,“ says Dr. Guy Chamberland, CEO and CRO. Confluence Pharmaceuticals and AOP Orphan Pharmaceuticals AG recently announced that they have signed a final agreement for the co-development and marketing of confluence`s main asset, a product to treat fragile X syndrome in Europe and the Middle East. Confluence is a biopharmaceutical company focused on the development of therapeutic treatments for fragile X syndrome and autism spectrum disorders. AOP is an Austrian company specializing in the development and marketing of medicines for rare and complex diseases. Chapter 1 – IntroductionChapitre 2 – Trends in co-development-dealmaking2.1. Introduction2.2. Definition of co-development agreements2.3. Success factors for co-development agreements2.4. When co-development can be useful2.5.

Attributs de Co-Development-Deals2.6. Orient partners to make co-development work2.7. Trends in co-development agreements since 20142.7.1. Co-Development-Dealmaking per year, 2014-20192.7.2. Co-Development-Dealmaking after development phase, 2014-20192.7.3. Co-Development-Dealmaking by branch, 2014-20192.7.4. Co-Development Dealmaking by Processing Branch, 2014-20192.7.5. Co-development-dealmaking by technology type, 2014-20192.7.6. Co-Development-Dealmaking by the most active company, 2014-20192.8. Possibility of development2.9. The future of co-development agreementsChapitre 3 – Overview of the structure of co-development agreements3.1.

Introduction3.2. Pure versus Multi-component co-development deals3.3. Structure of pure co-development agreements3.3.1. Example of co-development agreements3.3.1.a. Case Study 1: Ambrx – Zhejiang Medicine3.3.1.b. Case Study 2: UniQure – ChiesiChapter 4 – Leading Co-development deals4.1. Introduction4.2. Top Co-Development Deals by ValueChapitre 5 – Top 25 Most Active Co-Development Dealmakers5.1. Introduction5.2. Top 25 most active co-development dealmakersChapitre 6 – Co-Development Deal Term financials6.1. Introduction6.2.

Co-Development Partnering Headline 6.3. Co-development agreement Advances6.4. Co-development of the payment agreement step by step6.5.